Gastrointestinal Bleeding and Endoscopic Outcomes in Patients with SARS-CoV-2

Pradhan, Faruq; Alishahi, Yasmin

doi:10.5946/ce.2020.244

Cited by 5 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After taking into account the title and abstract, 902 articles were further eliminated, leaving 87 papers that could be considered plausible for this analysis after passing the article review. Based on thorough review and inclusion criteria, 21 articles totaling 26,933 COVID‐19 were eventually included in this meta‐analysis 6,11–30 . Table 1 summarises the baseline characteristics of the studies that were included.…”

Section: Resultsmentioning

confidence: 99%

“…Based on thorough review and inclusion criteria, 21 articles totaling 26,933 COVID-19 were eventually included in this meta-analysis. 6,[11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] Table 1 summarises the baseline characteristics of the studies that were included. The included patients had a median age of 65 years, with 34% of them being female.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and outcomes of upper gastrointestinal bleeding in COVID‐19: A systematic review and meta‐analysis

Rathore,

Wint,

Goyal

et al. 2024

Reviews in Medical Virology

View full text Add to dashboard Cite

Upper gastrointestinal bleeding (UGIB) in COVID‐19 presents challenges in patient management. Existing studies lack comprehensive review due to varied designs, samples, and demographics. A meta‐analysis can provide valuable insights into the incidence, features, and outcomes of UGIB in COVID‐19. A comprehensive literature search was carried out using several databases. We considered all appropriate observational studies from all over the world. Mantel‐Haenszel odds ratios and associated 95% confidence intervals (CIs) were produced to report the overall effect size using random effect models. Besides, Random effects models were used to calculate the overall pooled prevalence. Funnel plots, Egger regression tests, and Begg‐Mazumdar's rank correlation test were used to appraise publication bias. Data from 21 articles consisting of 26,933 COVID‐19 patients were considered. The pooled estimate of UGIB prevalence in patients admitted with COVID‐19 across studies was 2.10% (95% CI, 1.23–3.13). Similarly, the overall pooled estimate for severity, mortality, and rebleeding in COVID‐19 patients with UGIB was 55% (95% CI, 37.01–72.68), 29% (95% CI, 19.26–40.20) and 12.7% (95% CI, 7.88–18.42) respectively. Further, UGIB in COVID‐19 patients was associated with increased odds of severity (OR = 3.52, 95% CI 1.80–6.88, P = 0.001) and mortality (OR = 2.16, 95% CI 1.33–3.51, P = 0.002) compared with patients without UGIB. No significant publication bias was evident in the meta‐analysis. The results of our study indicate that UGIB in individuals with COVID‐19 is linked to negative outcomes such as severe illness, higher mortality rates, and an increased risk of re‐bleeding. These findings highlight the significance of identifying UGIB as a significant complication in COVID‐19 cases and emphasise the importance of timely clinical assessment and proper treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Prevalence and outcomes of upper gastrointestinal bleeding in COVID‐19: A systematic review and meta‐analysis

Rathore,

Wint,

Goyal

et al. 2024

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…EGD of the four cases revealed variable degrees of ulcerations in the gastric mucosa or esophagus, and endoscopic intervention was required in three patients. 18 In comparison with our cohort, anticoagulation was used in all admitted COVID-19-infected patients per our local protocol. It is considered a therapeutic option for COVID-related hyper-coagulation and at the same time may simultaneously exacerbate the risk of GI bleeding in vulnerable patients.…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal Bleeding in COVID-19 Infected Patients, and Management Outcomes

Al Hanaei,

AlKindi,

Alkhemeiri

et al. 2024

IJGM

View full text Add to dashboard Cite

Introduction Gastrointestinal bleeding in COVID-19-infection poses unique challenges to patients owing to the high risk of concomitant respiratory failure. However, endoscopic care providers are prone to transmission. This study aimed to understand the risk and management outcomes of gastrointestinal bleeding in COVID-19-infected patients. Methods Data were abstracted from electronic patient medical records, using ICD 10 codes, and demographic and clinical data were collected, for COVID-19-infected patients who developed gastrointestinal (GI) bleeding. Complications related to COVID-19 infection and management outcomes of GI bleeding were studied. Statistically, descriptive analysis was used because of the small sample size. Results Eighteen COVID-19-infected patients developed episodes of GI bleeding, yielding a prevalence of 0.45%. Their mean age was 74.8 years, 55.5% were female, and 66.6% of patients (n=12) had upper GI bleeding symptoms, predominantly melena (55.5%), followed by coffee ground nasogastric aspirates (n=2). Only two patients (11.11%) had episodes of lower GI bleeding, and the remaining four patients (22.2%) had recurrent acute anemia requiring blood transfusion. The Glasgow-Blatchford score (GBS) at presentation ranged between 6 to 16 (mean 8.8) and seven patients (38.8%) underwent endoscopic evaluation for GI bleeding. The predominant comorbid conditions included hypertension (22.2%), diabetes mellitus (27.7%), chronic kidney disease (50%), ischemic heart disease (33%), atrial fibrillation (11.1%), and peripheral vascular disease (11.1%). The median hospitalization was 24.6 days (range: 3–54 days). The 30-day mortality rate in our cohort was 22.2%, (4/18) mainly noted in older patients aged> 60 years with comorbid conditions and severe COVID-19 infection. Conclusion The prevalence of GI bleeding observed in our cohort was approximately 0.45%, significantly lower than the global prevalence observed, majority (66%) had upper GI bleeding. The exact reasons for the observed low prevalence of GI bleeding cannot be explained and will be the subject of future research.

show abstract

“…6 There are a small number of studies on the management of UGIB in COVID-19-positive symptomatic patients, and these studies recommend conservative treatment instead of endoscopy. [16][17][18][19][20] In a study by Martin et al, only onethird of the COVID-19-positive patients with UGIB underwent endoscopy, and the remaining patients received conservative treatment. 21 Cavaliere et al suggested that COVID-19-positive patients with UGIB should be followed primarily with conservative treatment in the first 24 hours, and endoscopy should be performed in case of no response.…”

Section: Discussionmentioning

confidence: 99%

Has the Number of Upper Gastrointestinal Bleeding Cases Presenting to the Emergency Department Decreased During the COVID-19 Pandemic?: A Single-Center Experience

Buyruk¹,

ARTUT²,

ŞENKAYA³

et al. 2022

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

In the period of the coronavirus disease-19 (COVID-19) pandemic, upper gastrointestinal endoscopy was either postponed or canceled, except for emergencies, due to the high risk of transmission. Our study aimed to evaluate the effect of the COVID-19 pandemic on patients with upper gastrointestinal bleeding presenting to the emergency department and to compare it with the data before the pandemic. Material and Methods: In this single-center, retrospective study, patients were divided into 2 groups: pre-COVID-19 (pre-C) (March 2019-March 2020) and post-COVID-19 (post-C) (March 2020-March 2021). Patients who presented to the emergency department with upper gastrointestinal bleeding during these periods and underwent endoscopic examination were included in the study. Results: Endoscopy for upper gastrointestinal bleeding was urgently performed in 125 patients in the pre-C period and in 89 (29% decrease) patients in the post-C period. The Glasgow-Blatchford Score was higher in the pre-C period (p=0.02). Peptic ulcers were the most common cause of bleeding in both groups. High-risk peptic ulcer (forrest 1a/1b/2a/2b), and malignancy were observed more frequently in the post-C period (p=0.003, p=0.04; respectively). Endoscopic combined treatment rate was higher in the post-C group (p<0.001). Re-bleeding ratios were similar for both the groups (p=0.48). Conclusion: During the post-C period, the number of upper gastrointestinal bleeding cases admitted to the emergency department decreased significantly. However, the rate of high-risk peptic ulcer and malignancy in the etiology of upper gastrointestinal bleeding increased in the post-C period.

show abstract

Gastrointestinal Bleeding and Endoscopic Outcomes in Patients with SARS-CoV-2

Cited by 5 publications

References 5 publications

Prevalence and outcomes of upper gastrointestinal bleeding in COVID‐19: A systematic review and meta‐analysis

Prevalence and outcomes of upper gastrointestinal bleeding in COVID‐19: A systematic review and meta‐analysis

Gastrointestinal Bleeding in COVID-19 Infected Patients, and Management Outcomes

Has the Number of Upper Gastrointestinal Bleeding Cases Presenting to the Emergency Department Decreased During the COVID-19 Pandemic?: A Single-Center Experience

Contact Info

Product

Resources

About